,,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['bcsm', 'enhertu', 'destiny-breast03', 'breast', 'kadcyla']
first up: on destiny-breast03, showing continued increased efficacy of tdxd (enhertu) vs tdm1 (kadcyla), and updated safety data. nausea/vomiting more common (antiemetics now recommended), pneumonitis in 11% but all but 2 were grade 1 or 2. #asco22 #bcsm 
(former) doctor, mother, woman LIVING with metastatic breast cancer. Grant reviewer. Conference goer. METAvivor board member. She/her. #NotDeadYet for 8 years